Show simple item record

dc.contributor.authorMoeginger, Uwe
dc.contributor.authorResemann, Anja
dc.contributor.authorMartin, Christopher E
dc.contributor.authorParameswarappa, Sharavathi
dc.contributor.authorGovindan, Subramanian
dc.contributor.authorWamhoff, Eike-Christian
dc.contributor.authorBroecker, Felix
dc.contributor.authorSuckau, Detlev
dc.contributor.authorPereira, Claney Lebev
dc.contributor.authorAnish, Chakkumkal
dc.contributor.authorSeeberger, Peter H
dc.contributor.authorKolarich, Daniel
dc.date.accessioned2017-05-29T12:34:40Z
dc.date.available2017-05-29T12:34:40Z
dc.date.issued2016
dc.identifier.issn2045-2322
dc.identifier.doi10.1038/srep20488
dc.identifier.urihttp://hdl.handle.net/10072/337588
dc.description.abstractProduction of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM197). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal epitopes. While the glycan is structurally defined, the attachment sites on the protein are not. Fully characterized conjugates and batch-to-batch comparisons are the key to eventually create completely defined conjugates. A variety of glycoconjugates consisting of CRM197 and synthetic oligosaccharide epitopes was characterised using mass spectrometry techniques. The primary structure was assessed by combining intact protein MALDI-TOF-MS, LC-MALDI-TOF-MS middle-down and LC-ESI-MS bottom-up approaches. The middle-down approach on CNBr cleaved glycopeptides provided almost complete sequence coverage, facilitating rapid batch-to-batch comparisons, resolving glycan loading and identification of side products. Regions close to the N- and C-termini were most efficiently conjugated.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherNature Macmillan
dc.relation.ispartofpagefrom20488-1
dc.relation.ispartofpageto20488-13
dc.relation.ispartofjournalScientific Reports
dc.relation.ispartofvolume6
dc.subject.fieldofresearchBiochemistry and Cell Biology not elsewhere classified
dc.subject.fieldofresearchBiochemistry and Cell Biology
dc.subject.fieldofresearchOther Physical Sciences
dc.subject.fieldofresearchcode060199
dc.subject.fieldofresearchcode0601
dc.subject.fieldofresearchcode0299
dc.titleCross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.description.versionPublished
gro.rights.copyright© The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
gro.hasfulltextFull Text
gro.griffith.authorKolarich, Daniel


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record